{Reference Type}: Journal Article
{Title}: MiR-9-3 hypermethylation is associated with stages of diabetic retinopathy.
{Author}: de Sousa BRV;Silva AS;de Assis CS;Diniz TG;Viturino MGM;de Queiroga Evangelista IW;Cavalcante-Silva LHA;Keesen TSL;de Oliveira NFP;Persuhn DC;
{Journal}: J Diabetes Metab Disord
{Volume}: 23
{Issue}: 1
{Year}: 2024 Jun
暂无{DOI}: 10.1007/s40200-024-01411-9
{Abstract}: <B>UNASSIGNED: </B>To investigate the potential relation between methylation of miR-9-3 and stages of diabetic retinopathy (DR). Additionally, we explored whether miR-9-3 methylation impacts the serum levels of Vascular Endothelial Growth Factor (VEGF).<BR><B>UNASSIGNED: </B>A cross-sectional study was conducted with 170 participants with type 2 diabetes, including a control group (n = 64) and a diabetes retinopathy group (n = 106), which was further divided into NPDR (n = 58) and PDR (n = 48) subgroups. Epidemiological, clinical, anthropometric, biochemical ELISA assay were analysed. DNA extracted from leukocytes was used to profile miR-9-3 methylation using PCR-MSP.<BR><B>UNASSIGNED: </B>MiR-9-3 hypermethylated profile was higher in the DR group (p < 0.001) and PDR subgroup compared to DM2 control group (p < 0.001). The hypermethylated profile in the PDR subgroup was also higher compared to NPDR subgroup (p < 0.001). There was no difference between DM2 control and NPDR group (p = 0.234). Logistic regression showed that miR-9-3 hypermethylation increases the odds of presenting DR (OR: 2.826; p = 0.002) and PDR (OR: 5.472; p < 0.001). In addition, hypermethylation of miR-9-3 in the DR and NPDR subgroup was associated with higher serum VEGF-A levels (p = 0.012 and p = 0.025, respectively).<BR><B>UNASSIGNED: </B>The methylation profile of the miR-9-3 promoter increases the risk of developing PDR. Higher levels of VEGF-A are associated with miR-9-3 hypermethylated profile in patients in the DR and NPDR stages.<BR><B>UNASSIGNED: </B>The online version contains supplementary material available at 10.1007/s40200-024-01411-9.